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Abstract
The last two decades have witnessed striking advances in our understanding of the biological
factors underlying the development of Follicular lymphoma (FL). Development of newer treatment
approaches have improved the outlook for many individuals with these disorders; however, with
these advances come new questions. Given the long-term survival of patients with FL, drugs with
favourable side-effect profile and minimal long-term risks are desired. FL is incurable with current
treatment modalities. It often runs an indolent course with multiple relapses and progressively
shorter intervals of remission. The identification of new targets and development of novel targeted
therapies is imperative to exploit the biology of FL while inherently preventing relapse and
prolonging survival. This review summarizes the growing body of knowledge regarding novel
therapeutic targets, enabling the concept of individualized targeted therapy for the treatment of FL.
Introduction
Non-Hodgkin's Lymphoma (NHL) represents the fifth-
leading cause of cancer deaths in the United States and the
second-fastest growing cancer in terms of mortality. The
incidence rate of NHL has nearly doubled in the last four
decades with an annual increase of 4%, due to reasons
that are not entirely clear. Approximately 180 Americans
are diagnosed with NHL each day [1].
Follicular Lymphoma (FL) is the second most common
form of NHL prevailing in the United States [2]. Most
patients have a widely spread disease at diagnosis, with
involvement of multiple lymph nodes, liver and spleen.
Marrow biopsy is positive in 40% of the patients at diag-
nosis [3]. Despite an advanced stage, the clinical course of
disease is usually indolent, with waxing and waning lym-
phadenopathy over a period of many years. The disease,
however, is not curable with available treatment [4,5],
and most patients tend to relapse after treatment with
shorter intervals of remission in between. In approxi-
mately 30% of patients, the disease progresses more rap-
idly with transformation into Diffuse Large B-Cell
Lymphoma (DLBCL) and early death. The molecular biol-
ogy underlying this phenomenon and the factors associ-
ated with the risk of transformation are not entirely
known [6].
Incurability of FL with the current treatment, which
includes the frontline use of monoclonal antibody to
CD20, rituximab (Rituxan, Genentech Inc. and Biogen
Idec, USA), leaves a wide-scope for development of future
strategies to provide durable complete remissions (CR)
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and extended quality of life. Given the long-term survival
of patients with FL, drugs with favorable side-effect profile
and minimal long-term risks are preferred. Recent years
have witnessed a marked improvement in our under-
standing of the biological factors underlying the develop-
ment of FL. The identification of new targets and
development of novel targeted therapies is imperative to
exploit the biological indolence of FL while inherently
preventing relapse and prolonging survival.
Apoptotic pathway in follicular lymphoma
The term apoptosis has a Greek origin, meaning 'falling or
dropping off', which was coined by Kerr in 1972 to
describe the morphological processes leading to pro-
grammed cellular self-destruction [7]. It is a tightly regu-
lated and highly efficient pathway of cell death
characterized by cell shrinkage, chromatin condensation,
and membrane blebbing [8]. At the molecular level, it is a
chain of events with positive- and negative-regulatory
loops that eventually culminate in the activation of a pro-
teolytic cascade involving members of the caspase family.
The process of apoptosis can be divided into initiation
and execution phases. Initiation of apoptosis occurs by
signals from two alternative convergent pathways: the
extrinsic pathway which is receptor mediated, and the
intrinsic pathway which is initiated in mitochondria.
The extrinsic pathway involves death receptors, such as
type 1-TNF receptor and FAS (CD95). Death receptors
bind to their ligands, cross-link, and provide a binding
site for an adapter protein with a death domain (FADD).
FADD binds an inactive form of caspase-8 and -10 in
humans [8]. Multiple procaspase-8 molecules are brought
into proximity and cleave one another to generate active
enzymes, initiating the execution phase [8,9].
The intrinsic pathway is characterized by the release of
pro-apoptotic molecules into the cytoplasm from mito-
chondria. These molecules belong to the Bcl-2 family of
proteins. Bcl-2 and Bcl-XL are anti-apoptotic proteins that
reside in the mitochondrial membrane, but are replaced
by pro-apoptotic molecules when the cell is deprived of
survival signals. This leads to an alteration in mitochon-
drial permeability which releases cytochrome c that binds
to Apaf-1 in the cytosol, and this complex activates cas-
pase-9 [10]. Caspases-8 and -9 are initiator caspase
enzymes. After an initiator caspase is cleaved to generate
its active form, the enzymatic death program is set in
motion by rapid and sequential activation of executioner
caspases (caspases- 3, -6 and -7) [11].
A) Bcl-2 inhibitors
CED-3 and CED-4 were identified as genes essential for
programmed cell death (PCD), while CED-9 was found to
inhibit the process of apoptosis in C. elegans [12,13]. Vaux
and Adams described the first mammalian homolog of
CED-3 in 1988 and named it Bcl-2. Bcl-2 transfected B-
cells were found to be resistant to apoptosis, normally
induced in B-cells by IL-3 withdrawal. Thus, it was dem-
onstrated for the first time that tumorigenesis depends not
only on the ability to escape growth control but also on
the ability to escape apoptosis [14].
The Bcl-2 gene codes for a 25-kDa protein that resides on
the cytoplasmic face of the outer mitochondrial mem-
brane (OMM), nuclear envelope and endoplasmic reticu-
lum (ER). There are a total of 25 genes in the Bcl-2 family
known to date. The Bcl-2 and related proteins are a grow-
ing family of molecules that share at least one of four
homologous regions termed Bcl homology domains
(BH1 to BH4). These domains mediate homo- and heter-
otypic dimer formation amongst Bcl-2 family members
[15-18]. Bcl-2 and its similar pro-survival homologs, Bcl-
XL and Bcl-W, contain all four BH domains. The other pro-
survival members contain a minimum of two domains,
BH1 and BH2 [19].
Members of this family fall into three main groups based
on their structure and function: the anti-apoptotic pro-
teins, which include Bcl-2 and Bcl-XL; the pro-apoptotic
proteins, which can be further subdivided to include
multi-domain proteins, such as Bax and Bak; and lastly,
the Bcl homology domain 3 (BH3) only proteins, which
includes Bid, Bik, Bim, Bad, Puma and Noxa. The BH3-
only proteins are pro-apoptotic and display homology
with other family members only in the alpha helical and
amphipathic BH3 segments [18,19].
A balance between members of the Bcl-2 family is
believed to determine the permeability of the mitochon-
dria and release of proteins that mediate cell death [20].
The pro-survival proteins maintain organelle integrity
since Bcl-2 directly or indirectly prevents the release of
cytochrome c from mitochondria. In a normal cell, basal
levels of pro-survival Bcl-2 like proteins prevent Bax and
Bak from becoming activated. Upon transmission of stress
signals by the cell, BH3-only proteins become activated
and competitively bind to a hydrophobic groove on the
anti-apoptotic proteins, thereby neutralizing them. This
action displaces Bax and Bak and allows them to form
multimers that aggregate on the endoplasmic reticulum
(ER) and mitochondrial membranes, triggering a cascade
of events leading to cell death [21-23]. A central check-
point of apoptosis that occurs at the mitochondria is the
activation of caspase-9 [24]. The BH4 domain of Bcl-2 and
Bcl-XL can bind to the C-terminal portion of Apaf-1 and
consequently inhibits the association of caspase-9 with
Apaf-1[25].
The BH1 and BH2 domains of Bcl-2 family members (Bcl-
2, Bcl-XL and Bax) show a striking similarity to the overall
fold of the pore-forming domains of bacterial toxins.
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Therefore it has been suggested that Bax- and Bax-like pro-
teins might mediate caspase-independent death via chan-
nel-forming activity, which would promote the
mitochondrial permeability transition [26]. An inappro-
priately low rate of apoptosis may prolong the survival or
reduce the turnover of abnormal cells. This could facilitate
accumulation of chromosomal aberrations, leading to
uncontrolled proliferation and tumor initiation.
Bcl-2 as a Molecular Target
The characteristic cytogenetic alteration in FL is a translo-
cation involving the Bcl-2 gene: t(14;18)(q32;q21). This
translocation, which is present in approximately 85% of
FL cases, places Bcl-2 under the control of immunoglobu-
lin heavy chain (IgH) enhancer on chromosome 14,
resulting in constitutive overexpression of Bcl-2 [27,28].
Thus, de-regulated expression of this gene consequently
leads to impaired apoptotic signalling. Consequently
transfection of Bcl-2 in vitro is capable of increased cell via-
bility and decreased apoptosis of lymphoma cells which
additionally confer resistance of these cells to chemother-
apeutic drugs [29].
In the recent past, Bcl-2 has been established as a target for
improving the treatment of B-cell malignancies using anti-
sense oligodeoxynucleotides to reduce Bcl-2 gene expres-
sion [30]. Thus, addition of oblimersen to fludarabine
plus cyclophosphamide regime significantly increased the
complete and partial response rate (CR, PR) in patients
with relapsed or refractory chronic lymphocytic leukae-
mia (CLL) patients, particularly those that are fludarab-
ine-sensitive, as well as among patients who achieve
response during course of their disease [31].
A number of pharmacological approaches have been used
to identify Bcl-2 family inhibitors that mimic the actions
of the proapoptotic BH3 domains [32]. Structural studies
have revealed that BH1, BH2 and BH3 domains in anti-
apoptotic proteins fold into a domain containing hydro-
phobic groove on its surface. As discussed previously, the
BH3 domain of BH3 only proteins bind to this groove,
thus neutralizing the Bcl2-like proteins [33]. It has been
hypothesized that a small-molecule inhibitor (SMI) that
binds to this BH3 binding site in Bcl-2 may be capable of
blocking the heterodimerization of Bcl-2, leading to
aggregation of Bak and Bad.
Small molecule inhibitors (SMI) of Bcl-2
A. Apogossypol (ApoG2)
ApoG2 is a semi-synthetic analog of gossypol that was
shown to have modest affinity for Bcl-2, Bcl-XL and Mcl-
1[34]. Gossypol (Figure 1) is a natural polyphenolic alde-
hyde that was extracted in its racemic form from cotton-
seed and extensively investigated as a male contraceptive
agent [35]. However, the practical applications of its
important properties have been prevented by the toxicity
and unpleasant side effects, including emesis and
diarrhea. A considerable body of research indicated that
the toxicity of gossypol is related to the reactions of the
aldehyde groups on the molecule, suggesting that removal
of the aldehyde groups from a gossypol molecule could
theoretically reduce its toxicity. However, it was unclear if
gossypol's biological activity was also tied to the presence
of the reactive aldehyde groups. The negative enantiomer
of gossypol, AT-101, was found to be clinically active, its
use in humans was associated with hepatotoxicity and
gastrointestinal (GI) toxicity [36].
ApoG2 (Figure 2) was developed after eliminating the two
reactive aldehydes from gossypol. It has been found to
Chemical structure of GossypolFigure 1
Chemical structure of Gossypol.
Chemical Structure of ApogossypolFigure 2
Chemical Structure of Apogossypol.
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compete with the BH3 peptide-binding sites on Bcl-2, Bcl-
XL, Mcl-1, Bcl-W, and Bcl-B, but not Bfl-1, with IC50 value
of 0.5 to 2 μM [36]. Comparison of the in vitro activity of
gossypol and ApoG2 on the National Cancer Institute
(NCI) panel of 59 tumor cell lines has suggested that these
compounds have overlapping yet non-identical mecha-
nisms [37]. Our lab has shown that ApoG2 can activate
the initiator caspase-9, and the effector caspase-3, and
induce caspase cleavage at nanomolar concentrations. In
addition, ApoG2 activates PARP and AIF which have been
implicated in the final stages of apoptosis. It is likely that
ApoG2 binds to Bcl-2 and prevents its association with
BH3-only pro-apoptotic proteins, allowing the pro-apop-
totic proteins to participate in the execution of cell death.
When used as a single agent at 120 μmol/kg daily, ApoG2
exhibited in vivo cytoablative activity in Bcl-2-transgenic
mice as measured by weight, size, and B-cell counts in
spleen [37]. The Bcl-2-expressing B-cells from transgenic
mice were more sensitive to cytotoxicity induced by
ApoG2 than gossypol in vitro with LD50 values of 3 to 5μM and 7.5 to 10 μM, respectively. Using the maximum
tolerated dose (MTD) of gossypol for sequential daily dos-
ing during in vivo studies, apogossypol displayed superior
activity than gossypol in terms of reducing splenomegaly
and reducing B-cell counts in spleens of Bcl-2-transgenic
mice [37].
Additional studies from our laboratory have shown that
ApoG2 has potent anti-lymphoma effect in vitro on the
WSU-FSCCL cell line [38,39] exhibiting IC50 value which
is 9- and 18-fold lower when compared to TW-37 and gos-
sypol. TW-37 is a benzenesulfonyl derivative, which was
designed to target the BH3-binding groove in Bcl-2 where
proapoptotic Bcl-2 proteins, such as Bak, Bax, Bid, and
Bim bind. Our laboratory has demonstrated the in vivo
efficacy of TW-37 in WSU-DLCL2-SCID mouse xenografts
with tumor growth inhibition (T/C) value of 28%, tumor
growth delay (T-C) of 10 days and log10kill of 1.50. We
have also shown that ApoG2 could significantly increase
the life span of lymphoma-bearing SCID mice by at least
42%
Although another SMI viz. ABT-737 (discussed below) has
a considerably lower IC50 (8 and 30 nM) when used
against FL cell lines, it fails to bind to Mcl-1 posing a
potential problem since Mcl-1 expression may inherently
result in resistance. In comparison, ApoG2 targets all
these three anti-apoptotic proteins. ApoG2 as a single
agent has shown efficacy in treatment of FL and is likely to
be even more effective when used in combination with
standard chemotherapy.
B. ABT- 737
ABT-737 (Figure 3) was developed in collaboration
between IDUN and Abbott laboratories. It has been
shown to inhibit Bcl-XL, Bcl-2 and Bcl-W, but not Mcl-1,
Bcl-B and A1 [40]. The inability of the drug to neutralize
Mcl-1 may provide an explanation why certain tumors are
resistant to ABT-737. Experiments have shown that down-
regulation of Mcl-1 dramatically potentiates lethality of
ABT-737 by releasing Bak from both Bcl-XL and Mcl-1
which results in simultaneous induction of Bak and Bax
[41].
ABT-737 has demonstrated single agent efficacy against
human FL cell lines that overexpress Bcl-2. The drug has
also yielded very impressive results in a murine xenograft
model of lymphoma when given both as a single agent
and in combination with etoposide [42]. Mice tolerated
daily injections for three weeks with no adverse effects
except a decline in platelets and lymphocytes. When SCID
mice implanted with a human FL cell line were treated
with ABT-737, morbidity was noticeably delayed [42].
This drug is presently in phase II of clinical testing.
C. ABT- 263
ABT-263 (Figure 4) is a potent orally bioavailable SMI that
is structurally related to ABT-737. This Bad-like BH3 mim-
ick disrupts Bcl-2: Bcl-XL interactions with pro-apoptotic
proteins inducing cytochrome c release and subsequent
Chemical structure of ABT-737Figure 3
Chemical structure of ABT-737.
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apoptosis [43,44]. As with ABT-737, this agent does not
possess a high affinity for Mcl-1 [45]. Oral administration
of ABT-263 alone has previously been shown to induce
complete tumor regressions in xenograft models of small-
cell lung cancer and acute lymphoblastic leukaemia
[46,47].
Recently, ABT-263 in combination with Rapamycin has
shown significant efficacy in FL cell lines [48]. In
xenograft models of these tumors, rapamycin induced a
largely cytostatic response in the DoHH-2 and SuDHL-4
models. However, co-administration with ABT-263
induced significant tumor regression, with DoHH-2 and
SuDHL-4 tumors showing 100% overall response rates.
The phase IIa portion of a multicenter study is evaluating
ABT-263 in up to 40 subjects who have follicular and
aggressive NHL to obtain a preliminary assessment of effi-
cacy. The pharmacokinetic profile of ABT-263 has been
shown to be linear between 10 mg and 160 mg/dose. The
average terminal half-life of ABT-263 varied between 14
and 25 hours across all dose levels. It reduced the platelet
levels in a dose-dependent manner [49]. No other major
toxicity has been noted.
D. HA 14-1
HA 14-1 (Figure 5) was the first reported Bcl-2 binding
molecule identified by using a computer-aided design
strategy based on the predicted structure of Bcl-2 protein
[50]. It binds to the surface pocket of Bcl-2 with high affin-
ity, inhibiting the interaction with Bak, thereby triggering
dissipation of mitochondrial membrane potential and
activating caspases [51]
Skommer et al showed that HA 14-1 is a potent inducer of
apoptosis in human FL cells [52]. Moreover, HA14-1 sig-
nificantly enhanced dexamethasone- and doxorubicin-
mediated, but not vincristine-mediated, cytotoxicity and
apoptosis [53]. For this reason, use of HA14-1 may be an
efficient strategy to lower the tumor response dose of dox-
orubicin, decreasing its cardiotoxicity and nephrotoxicity
[53].
HA 14-1 has also shown an ability to enhance Brefeldin A
(BFA) mediated cell killing in FL cell lines [54]. BFA-
induced cell death is associated with profound ER stress,
mitochondrial breach and subsequent caspase cascade
activation with clear predominance of apoptosing cells at
a G1 phase of the cell-cycle [53,54]. The apoptosis
induced by HA 14-1 is cell-cycle specific, with the G1 and
S phases of the cells being targeted frequently. Combining
HA 14-1 with drugs acting on the G1 and/or S phase may
potentially be of value. However, HA 14-1 is an unstable
compound and decomposes very rapidly under physio-
logical conditions. Due to its instability and redox activ-
ity, a newer and stable molecule, viz. sHA 14-1 has been
developed, which has better in vitro activity against cancer
cells [53,54].
B) p53-MDM2 interaction inhibitors
The idea of creating a magical bullet that could help to
unlock wild-type p53 and re-gain its functional activity in
cancer cells is currently of interest and under experimental
investigation. The tetrameric phosphoprotein p53 plays a
central role in regulating the cell cycle in response to vari-
ous kinds of stress, such as oxidation or radiation [55-58].
In normal cells, p53 is highly unstable with half-life meas-
uring in minutes. However, the half-life increases signifi-
cantly in response to cellular stress, leading to activation
Chemical structure of ABT-263Figure 4
Chemical structure of ABT-263.
Chemical structure of HA 14-1Figure 5
Chemical structure of HA 14-1.
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of multiple downstream genes implicated in apoptosis,
senescence and cell cycle control. The p53 function has
been found to be impaired in nearly 50% of cancers by
either a mutation or deletion in the TP53 gene [59]. As a
consequence, activated p53 is detrimental to the prolifer-
ation of cancer cells.
MDM2 was initially found as a product of an oncogene
amplified in a mouse tumor cell line [59-62]. In non-can-
cerous cells, it binds to p53 as a complex and promotes its
degradation by ubiquitination [60]. Thus, deregulation of
MDM2 could provide significant growth advantage. The
MDM2 gene has been found to be over-expressed by
amplification in several cancers with the highest fre-
quency observed in soft tissue sarcomas. The primary
function of MDM2 is to regulate p53 levels. These two
molecules regulate each other through an autoregulatory
feedback loop (Figure 6). When the levels of p53 are ele-
vated, it transcribes the MDM2 gene, concurrently raising
the level of its protein product. MDM2, leading to inacti-
vation of p53 by either binding to the p53 transactivation
domain or facilitating its degradation by exporting p53
out of the nucleus. MDM2 also acts as an E3 ubiquitin
ligase targeting the p53 for degradation. Deletion of
MDM2 gene in mice is lethal, but can only be reversed by
simultaneous deletion of the TP53 gene [63,64]. In addi-
tion, genetically engineered mice expressing reduced lev-
els of MDM2 are small in size, have reduced organ weight,
and are radiosensitive [65], providing further evidence of
this protein-protein interaction. Protein-protein interac-
tions involve large and flat surfaces that are difficult to tar-
get by low molecular weight molecules. It is clear by now
that p53-MDM2 interface showcases a unique and rather
unusual protein-protein interaction [66]. The hydropho-
bic residues of Phe19, Trp23 and Leu26 project into a
deep and highly structured pocket on the MDM2 surface,
which can be targeted by a nonpeptide SMI, thus unlock-
ing and reactivating p53.
Small-Molecule Inhibitors of p53-MDM2 Interaction
In 2004, Vassilev et al described a class of antagonists that
targeted the p53-MDM2 interaction [67]. Identified from
a group of cis-imidazoline compounds, these were desig-
nated as Nutlins (see Figure 7). Based on crystallographic
studies nutlins have been shown to interact with the
hydrophobic cleft of MDM2, thus mimicking the binding
of the helical portion of p53. However, one of the enanti-
omers of this racemic mixture of compounds was found
to possess higher affinity for the binding site as compared
to others. The active enantiomers of the cis-imidazoline
analogues were named Nutlin- 1, -2 and -3.
The investigators showed that incubation of wild-type
p53 cancer cells with Nutlins for eight hours led to a dose-
dependent increase in the cellular levels of p53, MDM2
and p21. At 24 hours post-treatment, a significant G1/M
phase fraction was observed with depletion of S phase
suggesting cell cycle arrest. This alteration was not
observed in cell lines with mutant or deleted p53 cancer
cell lines. Only cells with wild-type p53 respond to these
SMIs. Nutlin- 3a was administered for three weeks to nude
A representative pathway of p53-MDM2 autoregulatory loopFigure 6
A representative pathway of p53-MDM2 autoregulatory loop.
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mice bearing human cancer xenografts, which led to effec-
tive tumor inhibition and shrinkage.
Ding et al at the University of Michigan have identified
compounds with spiro-oxindole core structure as a new
class of SMIs targeting p53-MDM2 interaction [68]. Treat-
ment with MI-219 (Figure 8) induced p53 accumulation
and up-regulation of MDM2, p21, and PUMA, three p53-
target gene products, in SJSA-1 (osteosarcoma), LNCaP
and 22Rv1 (prostate cancer) cell lines with wild-type p53
in dose dependant manner [69].
However, restoring p53 activity in tumor cells could also
trigger p53 in normal tissues leading to deleterious conse-
quences. A genetic study showed that mice with 70%
reduced MDM2 expression developed normally but had
reduced body weight and mild disturbance in hematopoi-
esis with increased apoptosis in small intestine [70]. On
the other end of the spectrum, a study showed that p53
was spontaneously active in all tissues of MDM2 deficient
mice, causing severe toxicity and leading to rapid animal
death [71]. In comparison, activation of p53 by MI-219 is
always under the surveillance of MDM2 and is therefore
never fully out of control [69].
In our lab MI-319 (Figure 9), which is close analogue of
MI-219, had shown potent anti-lymphoma activity
against the WSU-FSCCL cell line in vitro and in vivo. Both
the compounds displayed comparable binding affinity for
the MDM2 protein in our fluorescence polarization-based
competitive binding assay. In the xenograft model that
was established by injecting 2 × 107 WSU-FSCCL cells per
mouse, treatment with MI-319 showed a significant ther-
apeutic impact (article in press).
C) Proteasome Inhibitors
The ubiquitin-proteasome pathway plays a key role in the
degradation of misfolded or unwanted intracellular pro-
teins in eukaryotic cells [72,73]. Despite help from chap-
erones, more than 80% of proteins fold incorrectly. Poly-
ubiquitination of these proteins targets them for degrada-
tion by the 26S proteasome, a highly conserved multi-pro-
tein complex [74]. This ATP dependent multi-catalytic
protease unit is present in numerous copies throughout
the cytosol and the nucleus. The 26S proteasome is com-
posed of a catalytic 20S core with four heptameric rings of
alpha and beta subunits stacked into a hollow cylinder
[75,76]. Two 19S subunits, containing proteasome activa-
tors that recognize tagged proteins for degradation, are
found at the end of this cylinder.
Nutlins, newly designed Small-Molecule Inhibitors of p53-MDM2 i teractionsFigure 7
Nutlins, newly designed Small-Molecule Inhibitors of 
p53-MDM2 interactions.
Structure of MI-219, a MDM2 inhibitorFigure 8
Structure of MI-219, a MDM2 inhibitor.
Chemical structure of MI-319Figure 9
Chemical structure of MI-319.
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Some of the proteins targeted by this complex include
p53, p21, p27, the inhibitory protein (I-.B), and Bcl-2
respectively [77]. Preclinical studies have shown that inhi-
bition of this pathway can lead to inhibition of tumor
metastasis, angiogenesis and induction of cell death. Fur-
thermore, malignant cells are much more sensitive to the
effects of proteasome inhibition than normal cells
[78,79].
The ubiquitin-proteasome pathway is a key mechanism in
deciding the activity of cell-cycle regulatory proteins. Inac-
tivation of mitotic cyclin dependent kinases (CDKs) by
proteolytic destruction of B-type cyclins was the first cell-
cycle regulatory event shown to be mediated by a ubiqui-
tin-dependent proteasomal pathway [80-82]. The ordered
degradation of p21 and p27 is required for progression
through cell-cycle and mitosis. Uncontrolled activity of
p21 and p27 can cause cell-cycle arrest by inhibition of
CDK. It is now known that the SCF family of ubiquitin-
protein ligases is responsible for protein ubiquitinylation
in the G1/S phase and the related APC/cyclosome com-
plexes perform the same function in G2/M. We are only
beginning to understand the extent to which deregulation
of cell-cycle regulators contributes to human cancer.
In addition, the ubiquitin-proteasome system plays a crit-
ical role in the degradation of IK-kB, an intracellular pro-
tein that acts as a negative regulator of nuclear factor
kappaB (NF-B) [83-85]. NF-.B is responsible for the acti-
vation of several genes that promote cell proliferation,
cytokine release, anti-apoptosis, and changes in cell sur-
face adhesion molecules. NF-B is sequestered in the cyto-
plasm when complexed with IK-B, and cannot enter the
nucleus to promote transcriptions of all its target genes.
Hence, stabilization of IB through proteasome inhibition
would prevents NF-B activation, making cells more sus-
ceptible to environmental stress and cytotoxic agents. The
overexpression of the pro-survival protein Bcl-2 in follicu-
lar lymphoma due to the translocation of the gene
t(14;18)(q32;q21) can be mediated through the inhibi-
tion of the 26S proteasome, which could make FL cells
particularly vulnerable to inhibitors of this pathway.
Bortezomib in Follicular Lymphoma
Bortezomib (Velcade, Millenium Pharmaceuticals) (Fig-
ure 10)was the first member of a new class of proteasome
inhibitors to be evaluated in human trials. It has been
approved by FDA for treatment of patients with multiple
myeloma, from diagnosis till relapse and beyond. Pre-
clinical studies have demonstrated encouraging results
with this proteasome inhibitor in NHL cell lines [84]. It
has been shown to induce apoptosis in primary effusion
lymphoma (PEL) cell lines through upregulation of p21,
p27 and p53 [86,87]. It was shown to be effective in
inhibiting cells from both FL and MCL patients with the
median IC50 being significantly lower for MCL [88]. This
drug was further shown to prevent tumor growth in MCL-
xenografted mice [89]. More encouraging results have
been seen with combination therapy involving borte-
zomib. It has been shown that synergistic effect with bort-
ezomib is even greater if cells are sequentially treated with
vincristine or doxorubicin and then bortezomib [90]. Pre-
treatment with bortezomib has also been found to be
more beneficial when used in combination with paclit-
axel or doxorubicin in PEL cell lines [87].
Several Phase II studies subsequently undertaken in the
past few years have established the efficacy of this novel
drug in various subtypes of NHL. In 2006, FDA approved
the use of bortezomib in patients with mantle cell lym-
phoma (MCL) who have received at least one chemother-
apy regimen, based on the findings of the PINNACLE trial
[91]. This prospective, multi-center, single-arm, open-
label study was undertaken in patients with MCL whose
disease progressed following at least one prior therapy.
Overall response rate was 31% with complete response
(CR + CRu) rate of 8 percent. The median duration of
response of 9.3 months and 15.4 months in patients were
achieving a CR.
Preliminary data from several ongoing studies indicates
that bortezomib is an effective agent in FL with some
Structure of a new clinically approved proteasome inhibitor, BortezomibFigure 10
Structure of a new clinically approved proteasome 
inhibitor, Bortezomib.
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durable overall responses (ORRs) of 18-60%. In an NCI-
sponsored phase 2 study, bortezomib was given to
patients with relapsed indolent NHL on the conventional
schedule of twice weekly for 2 out of 3 weeks (1.5 mg/m2)
[92]. The ORR in 19 patients with FL was 60% with 1 CR,
1 Cru and 7 PR. Another phase II study in patients with
relapsed or refractory B-cell NHL reflected one possible
Cru out of 5 patients with FL [93]. A third study by Strauss
et al used bortezomib at 1.3 mg/m2 with conventional
schedule and showed that 2 out of 11 evaluable patients
achieved a PR for an ORR of 18% three months after treat-
ment [94]. As compared to the previous study with greater
response rates, treatment was discontinued in non-
responders, even without progression.
It has been suggested that the time to response in FL may
be longer than other lymphomas due to its indolent
course, suggesting a need for prolonged treatment. Opti-
mizing the dosing and the schedules will also be a chal-
lenge given the biological heterogeneity of FL and the
varying synergistic interactions with other SMIs.
D) TRAIL activators
Another successful effort in developing selective SMIs for
cancer therapy has been targeting death receptors on the
extra-cellular membrane. TRAIL is expressed constitu-
tively on a subset of natural killer (NK) cells in liver and
may be induced on monocytes, dendritic cells, B-cells and
T-cells by signal from TLRs or interferons. Five receptors
for TRAIL have been identified, two of which, death recep-
tor DR4 (TRAIL-R1) and DR5 (TRAIL-R2), are capable of
transducing the apoptosis signal.
After binding of either the ligand or agonist antibody to
the extracellular domain of TRAIL-R1, a death-inducing
signaling complex (DISC) that includes Fas-associating
protein is formed with FADD and caspase-8 or -10 [95].
Once activated, this cascade of caspases degrades critical
regulatory proteins and DNA, resulting in the characteris-
tic morphology of PCD [96]. Expression of DR4 & -5 is
frequently detected in human cancers including colon,
gastric, pancreatic, ovarian, breast and non-small-cell lung
cancer, with low or no expression in normal tissues [97].
Zerafa et al demonstrated the role of TRAIL as a tumor
suppressor in mice that are mutant for one p53 allele.
TRAIL deficiency predisposed mice to a greater number of
tumors, including disseminated lymphomas and sarco-
mas [98]. In fact, greater than 25% mice developed lym-
phoid malignancies after 500 days of life.
Triggering the TRAIL receptor could be an effective means
of targeting cancer cells with inactivated p53 mutations
because death-receptor mediated cell death is independ-
ent of p53. In this effort, agonistic antibodies to DR4 and
DR5 have been generated. Recently, a mouse agonistic
antibody against DR5, TRA-8, has been shown to have
strong tumoricidal activity in vivo [99]. It has shown to be
very effective in human breast cancer xenograft model
[100]. These new class of antibodies are moving at a swift
pace from benchside to the clinic.
TRAIL in Follicular Lymphoma
To establish if TRAIL could be a potential therapeutic tar-
get in FL, Travert et al estimated its potency to induce
apoptosis on B-cells from FL patients [101]. After a 24
hour treatment with 500 ng/ml TRAIL on cells extracted
from lymph nodes recovered from patients with FL at
diagnosis, the percentage of active caspase 3-positive cells
on CD19+CD20+ B lymphocytes were estimated by flow
cytometry. All the patients (n = 11) were found to be sen-
sitive to TRAIL. A 30% increase of active caspase 3-positive
primary FL B-cells according to the control was noted.
Interestingly, an average 20% of active caspase 3-positive
non-treated cells were detected reflecting spontaneous
apoptosis after 24 hours of culture, thus underlining the
potential role of tumor micro-environment in the patho-
genesis of FL.
On the other hand, a phase I study with the agonistic anti-
body Mapatumumab showed that this molecule has no
significant hematological toxicity [102]. Similarly, a phase
II trial targeting DR4 in patients with relapsed/refractory
NHL has reported an objective response in 14 patients
with FL, including one CR [103]. It is becoming clear that
one critical determinant of response is the selection of
optimal patients and chemotherapy regimens to be com-
bined with TRAIL receptor-targeting agents. Examination
of drug resistant FL cell lines has revealed that mutations
that inhibit the upregulation of p53 or expression of cas-
pase-3 in the TRAIL pathway severely affect the ability of
DNA-damaging drugs to circumvent the anti-apoptotic
Bcl-2 block in FL [104]. Additional studies show that
mutational inactivation of Bax and overexpression of Bcl-
2 cause resistance to death receptor mediated apoptosis
[104]. It can thus be foreseen that using agents that restore
p53 function (such as the MDM2 inhibitors) or immuno-
logical agents like Rituximab in pairing with agonistic
TRAIL antibody could enhance responses to standard
chemotherapy agents by overcoming tumor cell resist-
ance.
E) Thymoquinone as an apoptosis inducing agent 
for follicular lymphoma
Thymoquinone (TQ) (Figure 11) is an active constituent
of volatile oil of black Nigella sativa seed with biological
activities that we have detailed in our recent report [105].
TQ has good safety profile with LD50 value of 104.7 and
57.5 mg/kg after i.p. injection and 870.3 and 794.3 mg/kg
after oral treatment in mice and rats respectively [106].
Despite its impressive safety profile and potent anticancer
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activity, there are no reports available in the literature
about use of TQ in the treatment of FL. We have per-
formed limited in vitro studies using a WSU-FSCCL cell
line and found that TQ can inhibit up to 50% cell growth
by using 3 micro-molar concentrations. In this review we
provide rationale to explore the use of TQ for the treat-
ment of FL.
The anti-proliferative effect of TQ has been studied in can-
cer and normal cell lines, viz. canine osteocarcinoma
(COS31) and its cisplatin-resistant variant (COS31/
rCDDP), human breast adenocarcinoma (MCF-7),
Human ovarian adenocarcinoma (BG-1) and Mandin-
Darby canine (MDCK) cells respectively [107]. The cell
cycle checkpoints allow the cells to correct possible defects
and avoid progression to cancer [108,109]. There are two
major checkpoints to identify DNA damage: one at the
G1-S transition which prevents the replication of dam-
aged DNA and other at the G2-M transition that prevents
non-intact chromosome segregation. The apoptosis
inducing activity of TQ was found to be due to its effects
on the expression of cell cycle regulatory proteins. TQ
inhibit G1 phase of cell cycle via increase in the expression
of the cyclin-dependent kinase inhibitor p16 and down-
regulation of cyclin D1 protein expression in papilloma
cells [110]. Treatment with TQ in HCT-116 cells has been
found to lead to G1 arrest associated with up-regulation of
p21WAF1 cells which blocks CDK2 activity and possibly
CDK4 and CDK6 activities which were suggested the prin-
cipal transcriptional target of p53 in the context of the G1
checkpoint [111]. TQ was also found to arrest G2/M
phase of cell cycle which was associated with an increase
in p53 expression and down-regulation of cyclin B1 pro-
tein in spindle carcinoma cells. TQ induced apoptosis was
mediated via p53 which can regulate G2/M transition
through either induction of p21 or 14-3-3sigma, a protein
that normally sequesters cyclin B1-CDC2 complexes in
the cytoplasm [112-115]. Antiproliferative and pro-apop-
totic effects of TQ are mediated by induction of p53-
dependent apoptosis in human colon cancer cells which
is supported with a study by Roepke and colleagues [116]
in two human osteosarcoma cell lines with different p53
mutation status using flow cytometry and DNA damage
assays. TQ induced a much larger increase in the Pre-G1
(apoptotic) cell population, but no cell cycle arrest in
MG63 cells, in the flow cytometric analysis, on other hand
TQ was confirmed to induce greater extent of apoptosis in
p53 null MG63 cells by using three DNA damage assays.
The upregulation of p21WAF1 was associated with G2/M
arrest in MNNG/HOS cells. Both cell lines did not show
any modulation of Bax/Bcl-2 ratios. The apoptosis
induced by TQ showed involvement of the mitochondrial
pathway due to cleavage of caspases-9 and -3 in MG63
cells. TQ triggers apoptosis in a dose and time-dependent
manner, starting at a concentration of 100 μM after 12 h
of incubation which is associated with a 2.5 to 4.5 fold
increase in p53 and p21WAF1 mRNA expression and a sig-
nificant decrease in Bcl-2 protein levels in HCT-116 cells.
Co-incubation with pifithrin-α, a p53 inhibitor, restored
the Bcl-2, p53 and p21WAF1 levels to the untreated control
levels and absolved the effects of TQ [117].
Altogether, these results suggest that TQ is involved in
influencing cell cycle regulators involved in apoptosis as
well as in down-regulation of the anti-apoptotic proteins,
which is supported by similar effects on primary mouse
keratinocytes, papilloma (SP-1) and spindle carcinoma
cells respectively. At longer incubation times (48 h) the
compound induced apoptosis in both cell lines by
increasing the ratio of Bax/Bcl-2 protein expression and
down-regulating the Bcl-xL protein [118]. TQ has been
shown to initiate apoptosis even via p53-independent
pathways through activation of caspase-3, 8 and 9 in p53-
null myeloblastic leukemia HL-60 cells [119]. It was
observed that caspase-8 activity was highest after 1 h fol-
lowing the treatment of TQ, while caspase-3 activity was
highest after 6 h respectively. These observations were
explained on the basis of up-regulation of pro-apoptotic
Bax protein along with down-regulation of antiapoptotic
Bcl-2 proteins resulting in enhanced Bax/Bcl-2 ratio.
These results are also supported by reports in prostate and
other cancer cells [120-122].
Recently we found that TQ is very effective against FL,
DLCL and Hodgkin's in vitro. Usually, the IC50 of TQ
against cancer is high, but our recent data showed that the
IC50s for TQ against WSU-FSCCL, WSU-DLCL2 (non-
Hodgkin's) and KM-H2 (Hodgkin's) are between 1-3 μM,
which makes TQ a very important dietary supplement in
lymphoma. In addition, TQ combination with standard
chemotherapeutic regimen such as CHOP or R-CHOP
Structure of Thymoquinone extracted from Nigella sativa seedFigure 11
Structure of Thymoquinone extracted from Nigella 
sativa seed.
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(rituxin, cyclophosphamide, doxorubicin, vincristine and
prednisone) showed a better antilymphoma efficacy.
Recent studies on TQ have suggested that NF-kB is a legit-
imate target of its action in cell growth inhibition and
induction of apoptosis in cancer cells. TQ showed down-
regulation of gene products of NF-kB-regulated antiapop-
totic proteins (IAP1, IAP2, XIAP Bcl-2, Bcl-xL, and sur-
vivin), proliferative (cyclin D1, cyclooxygenase-2, and c-
Myc), and angiogenic factors (matrix metalloproteinase-9
and vascular endothelial growth factor) [123]. TQ also
showed dose- and time-dependent reduction of PDA cell
synthesis of MCP-1, TNF-alpha, interleukin (IL)-1beta
and COX-2, while after 24 h treatment it completely abol-
ishes inflammatory mediators in pancreatic cell line
[124]. In our previous study, we found out that TQ could
potentiate the killing of pancreatic cancer cells induced by
chemotherapeutic agents like gemcitabine or oxaliplatin
by down-regulation of nuclear factor-kappaB (NF-kap-
paB), Bcl-2 family, and NF-kappaB-dependent antiapop-
totic genes (X-linked inhibitors of apoptosis, survivin, and
cyclooxygenase-2) [125]. TQ also showed antiangiogenic
activity in vitro and in vivo in a xenograft human prostate
cancer (PC3) in mouse [126]. A recent report has identi-
fied checkpoint kinase 1 homolog, CHEK1, a serine/thre-
onine kinase, as the target of TQ, leading to apoptosis in
p53+/+ colon cancer cells. The study compared the effect
of TQ on p53+/+ as well as p53-/- HCT116 colon cancer
cells where the former were found to be more sensitive to
TQ in terms of DNA damage and apoptosis-induction. As
a possible explanation for such sensitivity, it was observed
that CHEK1 was up-regulated upto 9 folds in p53-null
HCT116 cells. Further, transfection of p53 cDNA and
CHEK1 siRNA in p53 null cells resulted in restoration of
apoptosis to the levels of p53+/+ cells. The in vivo results
demonstrated that tumors lacking p53 had higher levels
of CHEK1 which was associated with poorer apoptosis,
advance tumor stages and worse prognosis [127].
Thus, there is compelling evidence that TQ induces apop-
tosis through modulation of multiple targets and hence
constitutes as a promising phytochemical for initiation of
many types of cancer cells. As discussed in this review, tar-
geting Bcl-2, p53 and proteasome proteins for inducing
apoptosis is emerging as an efficient strategy for treatment
of FL. Since TQ has apoptosis inducing potential involv-
ing cell cycle arrest and upregulation of p53 followed by
downregulation of NF-kB, bcl-2 and activation of Cas-
pase-3,-9 pathways thus it is becoming increasingly clear
that it offers a new treatment option for FL.
Conclusion
Despite the impressive biological and therapeutic
progress made in dealing with FL over the last decade, and
a constantly growing number of FL patients being offered
more hope for the disease-free survival time, there is still
a substantial room for improving treatment. Tumor trans-
formation into a more aggressive phenotype and develop-
ment of resistance to standard chemotherapy regimens in
the course of FL remain the main causes of deaths in
patients with this type of lymphoma. A large number of
novel agents potentially useful in FL patients are in the
clinical trial pipeline which includes new chemotherapeu-
tics, bcl2 SMIs, monoclonal antibodies, apoptosis-induc-
ing agents, and immunomodulators. These therapies
could help to extend the duration of remission without
adding any further burden of toxicity. It is also becoming
clear that the therapy for FL also needs to be adapted to
the patient's individual status, depending on the aggres-
siveness of the disease, gene-signatures and tumor micro-
environment while relying on a continuously growing
repertoire of salvage therapies.
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